clinical trial · NCT07404553
A Study Of SHR-1918 In Participants With Hypercholesterolemia With Inadequate Lipid Control on Statins Plus PCSK9 Inhibitors
Beijing Suncadia Pharmaceuticals Co., Ltd·phase3·recruiting·n = 126
HypercholesterolemiaSHR-1918 InjectionSHR-1918 Injection Placebo
brief summary
The purpose of the study is to evaluate the efficacy and safety of SHR-1918 in patients with hypercholesterolemia with inadequate lipid control on statins plus PCSK9 inhibitors. The efficacy and safety of SHR-1918 will be evaluated after 12-weeks and 24-weeks treatment.
started
Apr 30, 2026
primary completion
Jul 1, 2028
completion
Aug 1, 2028
last updated
Jun 16, 2026
official title
A Multicenter, Randomized, Double-Blind, Placebo-Controlled Phase II/III Study to Evaluate the Efficacy and Safety of SHR-1918 in Patients With Hypercholesterolemia With Inadequate Lipid Control on Statins Plus PCSK9 Inhibitors
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol